Sumary of MET amplification as driver for some non-small cell lung cancers:
- Ross Camidge, MD, PhD, director of thoracic oncology at the University of Colorado School of Medicine and CU Cancer Center member, has helped to define MET amplification as a rare but potentially actionable driver for non-small cell lung cancer (NSCLC).
- Camidge says many of the major developments in the treatment of non-small cell lung cancer have come from defining molecularly specific subsets of the disease for which researchers have been able to develop targeted treatments.
- Until now, all of these subsets have been based on either genetic mutations or gene rearrangements (where two separate genes fuse to create an oncogene).
- “What we’ve started to realize is that non-small cell lung cancer isn’t just one disease,” Camidge says.
- ” Gene amplification as cancer driver The new paper, titled “Crizotinib in Patients With MET-Amplified NSCLC,” and published in the June issue of the Journal of Thoracic Oncology, introduces a third means of defining NSCLC subsets that can be targeted with a specific drug.
- Rather than a mutation or a gene rearrangement, this third category represents oncogene activation through gene amplification.
- Is it an increase in just that one gene because it’s so important to the cancer, or is it being dragged along for the ride by an increase in lots of other genes in the same part of the chromosome?
- ” For this study, Camidge and the other investigators in the Pfizer-sponsored study focused specifically on MET amplification.